Brainstorm Cell Therapeutics Inc. (BCLI)

Market Cap	11.22M
Revenue (ttm)	n/a
Net Income (ttm)	-11.09M
Shares Out	9.84M
EPS (ttm)	-2.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	153,696
Open	1.160
Previous Close	1.160
Day's Range	1.130 - 1.190
52-Week Range	0.723 - 6.450
Beta	0.21
Analysts	Strong Buy
Price Target	30.00 (+2,531.58%)
Earnings Date	Aug 13, 2025

About BCLI

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: BCLI
• Website: https://www.brainstorm-cell.com

Analyst Summary

According to one analyst, the rating for BCLI stock is "Strong Buy" and the 12-month stock price target is $30.0.

Price Target

$30.0

(2,531.58% upside)

Analyst Consensus: Strong Buy